Cargando…
Antibiotics in the clinical pipeline in October 2019
The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR) bacteria, especially Gram-negative (G−ve) pathogens, is acknowledged as one of the world’s most pressing health issues; however, the discovery and development of new, nontoxic antibacterials is not a straigh...
Autores principales: | Butler, Mark S., Paterson, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223789/ https://www.ncbi.nlm.nih.gov/pubmed/32152527 http://dx.doi.org/10.1038/s41429-020-0291-8 |
Ejemplares similares
-
Antibiotics in the clinical pipeline as of December 2022
por: Butler, Mark S., et al.
Publicado: (2023) -
Pipeline of Known Chemical Classes of Antibiotics
por: d’Urso de Souza Mendes, Cristina, et al.
Publicado: (2013) -
In the literature: October 2019
por: Tarazona, Noelia, et al.
Publicado: (2019) -
Reviewers for the Journal of Insect Science: (January 2019–October 2019)
Publicado: (2020) -
Acknowledgment to reviewers—November 2019 to October 2020
Publicado: (2020)